Studies

Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study.

Obesity pillars|2026|Trocchio L, Peters F|2 citations

BACKGROUND: Adequately treating obesity remains a fundamental goal for improving quality of life and long-term health outcomes. Semaglutide and tirzepatide have shown clinically meaningful weight loss in clinical trials, yet despite this weight loss…

Semaglutide Tirzepatide

PMID: 41399811

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.

Molecular metabolism|2026|Roell W et al.

BACKGROUND: Tirzepatide, a single-molecule dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor (R) agonist, has shown superiority in the reduction of blood glucose and body weight, above selective GLP-1R a…

Obesity in China: current progress and future prospects.

The lancet. Diabetes & endocrinology|2026|Pan X et al.|1 citation

The prevalence of overweight and obesity in China has continued to increase over the last decade, with mounting health and economic consequences. In this Personal View, we critically examine recent advances and identify current and emerging challenge…

ReviewSemaglutide Tirzepatide

PMID: 41389801

Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology|2026|Liu T et al.

This study aimed to evaluate the real-world effectiveness and psychiatric safety of tirzepatide among adults with schizophrenia spectrum disorders, focusing on the risks of mortality, hospitalization, and suicidal behavior. Based on the electronic he…

Tirzepatide

PMID: 41389474

The impact of nutrition, exercise, and pharmacotherapy on menstrual health in adolescents with overweight and obesity.

Nutrition (Burbank, Los Angeles County, Calif.)|2026|Wu J, Jacobson-Dickman E

BACKGROUND: Menstrual health is a critical marker of physiological and psychological well-being in adolescents. While undernutrition and energy deficiency are well-known causes of menstrual disruption through hypothalamic hypogonadal suppression, the…

ReviewSemaglutide Tirzepatide

PMID: 41386097

Current clinical application of incretin therapy for obesity management.

Canadian journal of physiology and pharmacology|2026|Skinner K, Clements J

Incretin therapy, utilizing glucagon-like peptide-1 (GLP-1) receptor agonists and dual receptor agonists, is a cornerstone of obesity management due to effects on appetite suppression, weight loss, and metabolic improvement. Liraglutide, semaglutide,…

ReviewSemaglutide Tirzepatide

PMID: 41420876

Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.

Diabetologia|2026|Neves J et al.

AIMS/HYPOTHESIS: Simultaneous control of HbA, lipid profile, BP and body weight is essential for preventing chronic complications of type 2 diabetes. Glucagon-like peptide-1 (GLP-1)-based therapies improve all these variables but whether the dual GLP…

Randomized Controlled TrialSemaglutide Tirzepatide

PMID: 41419618

GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.

Annals of plastic surgery|2026|Dhupati P et al.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for weight management and cardiometabolic health. Common peroneal neuropathy (CPN) associated with rapid weight loss is attributed to adipose tissue reduction and subsequent n…

Case ReportSemaglutide Tirzepatide

PMID: 41417708

Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice.

Life sciences|2026|Bittencourt J et al.|1 citation

This study investigated the therapeutic potential of tirzepatide, a dual GIP/GLP-1 receptor agonist, in a mouse model combining obesity, type 2 diabetes, and estrogen deficiency. Four groups were initially established and maintained for 12 weeks unde…

Animal StudyTirzepatide

PMID: 41412277

Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal dysfunction.

Brain research|2026|Marinho T et al.

Obesity, diabetes, and menopause impair hypothalamic regulation of energy balance by inducing inflammation, cellular stress, and disruption of neuropeptide signaling. In a female mouse model combining these conditions, we investigated whether tirzepa…

Animal StudyTirzepatide

PMID: 41407242

Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.

Diabetes research and clinical practice|2026|Iwasaki Y et al.

AIMS: To elucidate the overall protective effects of tirzepatide against atherosclerosis-related events, including cardiovascular and lower-extremity events. METHODS: We conducted a retrospective cohort study using the TriNetX global health research…

Tirzepatide

PMID: 41448390

Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol.

Obesity pillars|2026|Duncan J et al.

INTRODUCTION: Obesity and its downstream effects continue to drive rising rates of chronic disease. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant pot…

Tirzepatide

PMID: 41438798

A Convergent Hybrid Gram-Scale Synthesis of Tirzepatide: Tangential Flow Filtration Assisted Native Chemical Ligation-Desulfurization Approach.

Angewandte Chemie (International ed. in English)|2026|Jalan A et al.

The development of scalable and efficient manufacturing of high-volume complex synthetic peptides and proteins, like tirzepatide (TZP, 1), faces major hurdles due to the limitations of traditional Solid Phase Peptide Synthesis (SPPS) and Liquid Phase…

Tirzepatide

PMID: 41437654

Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.

American journal of ophthalmology|2026|Murray M et al.

PURPOSE: As use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for Type 2 diabetes (T2DM) and weight management increases, emerging research identifies various adverse drug reactions. This study aimed to expand this research base, focusing o…

Semaglutide Tirzepatide

PMID: 41429246

Development of a Long-Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP-1R Agonists for the Treatment of Obesity.

Bioconjugate chemistry|2026|Zhou Y et al.

Dual amylin and calcitonin receptor agonists (DACRAs) offer a promising strategy for treating obesity and related metabolic disorders but are limited by aggregation and the short half-lives of native peptides. Here, we report the design of a long-act…

Animal StudySemaglutide Tirzepatide

PMID: 41429154

Beyond metabolism: sexual dysfunction and weight-loss drugs.

Sexual medicine reviews|2026|Fuentes-Mendoza J et al.|1 citation

INTRODUCTION: Sexual dysfunction (SD) is a frequent and underrecognized complication of obesity, mediated by a complex interplay of hormonal, vascular, metabolic, and psychosocial pathways. Despite the established link between weight reduction and im…

ReviewTirzepatide

PMID: 41427954

A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection.

Annals of medicine and surgery (2012)|2026|Thiriveedi M et al.

Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, represents a new class of incretin-based therapy for type 2 diabetes mellitus (T2DM), obesity, and related comorbidities. Thi…

ReviewTirzepatide

PMID: 41496949

Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.

Obesity surgery|2026|Thiyagarajan S et al.

OBJECTIVE: To evaluate two-year costs to insured patients treated with Roux-en-Y gastric bypass (RYGB) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes (T2D) and obesity. METHODS: Using the 2017 to 2023 Merative™ claims da…

Semaglutide Tirzepatide

PMID: 41484761

Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.

Anais brasileiros de dermatologia|2026|El-Amawy H

Tirzepatide, a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Tirzepatide was first approved by the FDA for type 2 diabetes in May 2022 and subsequently for obesity in November 2023, and…

ReviewSemaglutide Tirzepatide

PMID: 41483501

Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study.

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.

Obesity in China: current progress and future prospects.

Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients.

The impact of nutrition, exercise, and pharmacotherapy on menstrual health in adolescents with overweight and obesity.

Current clinical application of incretin therapy for obesity management.

Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.

GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.

Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice.

Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal dysfunction.

Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.

Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol.

A Convergent Hybrid Gram-Scale Synthesis of Tirzepatide: Tangential Flow Filtration Assisted Native Chemical Ligation-Desulfurization Approach.

Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.

Development of a Long-Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP-1R Agonists for the Treatment of Obesity.

Beyond metabolism: sexual dysfunction and weight-loss drugs.

A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection.

Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.

Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.

Tirzepatide-induced body composition changes: Implications from the SURPASS-3 MRI substudy.